Data Insights

Siremadlin succinate by Novartis for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Siremadlin succinate is under clinical development by Novartis and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...

Likelihood of Approval and Phase Transition Success Rate Model - Siremadlin Succinate in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

JJO-686 by Novartis for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

JJO-686 is under clinical development by Novartis and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic...

Likelihood of Approval and Phase Transition Success Rate Model - JJO-686 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

Siremadlin succinate by Novartis for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval

Siremadlin succinate is under clinical development by Novartis and currently in Phase II for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Siremadlin Succinate in Post-Polycythemia Vera Myelofibrosis (PPV-MF)

Data Insights

Siremadlin succinate by Novartis for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Siremadlin succinate is under clinical development by Novartis and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According...

Likelihood of Approval and Phase Transition Success Rate Model - Siremadlin Succinate in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

Data Insights

Siremadlin succinate by Novartis for Myelofibrosis: Likelihood of Approval

Siremadlin succinate is under clinical development by Novartis and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Siremadlin Succinate in Myelofibrosis

Data Insights

Ribociclib succinate by Novartis for Glioblastoma Multiforme (GBM): Likelihood of Approval

Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ribociclib Succinate in Glioblastoma Multiforme (GBM)

Data Insights

Dabrafenib mesylate by Novartis for Hairy Cell Leukemia: Likelihood of Approval

Dabrafenib mesylate is under clinical development by Novartis and currently in Phase II for Hairy Cell Leukemia. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Dabrafenib Mesylate in Hairy Cell Leukemia

Data Insights

Trametinib dimethyl sulfoxide by Novartis for Relapsed Multiple Myeloma: Likelihood of Approval

Trametinib dimethyl sulfoxide is under clinical development by Novartis and currently in Phase II for Relapsed Multiple Myeloma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Trametinib Dimethyl Sulfoxide in Relapsed Multiple Myeloma

Data Insights

Sabatolimab by Novartis for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Sabatolimab is under clinical development by Novartis and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Sabatolimab in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

Data Insights

Sabatolimab by Novartis for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval

Sabatolimab is under clinical development by Novartis and currently in Phase II for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Sabatolimab in Post-Polycythemia Vera Myelofibrosis (PPV-MF)

Data Insights

Nisevokitug by Novartis for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Nisevokitug is under clinical development by Novartis and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Nisevokitug in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

Data Insights

Nisevokitug by Novartis for Myelofibrosis: Likelihood of Approval

Nisevokitug is under clinical development by Novartis and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Nisevokitug in Myelofibrosis

Data Insights

Nisevokitug by Novartis for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval

Nisevokitug is under clinical development by Novartis and currently in Phase II for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Nisevokitug in Post-Polycythemia Vera Myelofibrosis (PPV-MF)

Data Insights

Sabatolimab by Novartis for Myelofibrosis: Likelihood of Approval

Sabatolimab is under clinical development by Novartis and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Sabatolimab in Myelofibrosis

Data Insights

Crizanlizumab by Novartis for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Crizanlizumab is under clinical development by Novartis and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Crizanlizumab in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

Data Insights

Crizanlizumab by Novartis for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval

Crizanlizumab is under clinical development by Novartis and currently in Phase II for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Crizanlizumab in Post-Polycythemia Vera Myelofibrosis (PPV-MF)

Data Insights

Risk adjusted net present value: What is the current valuation of Novartis's Rapcabtagene autoleucel?

Rapcabtagene autoleucel is a gene-modified cell therapy commercialized by Novartis, with a leading Phase II program in Relapsed Chronic Lymphocytic...

Net Present Value Model: Novartis AG's Rapcabtagene autoleucel

Data Insights

Risk adjusted net present value: What is the current valuation of Novartis's Peptide to Antagonize GRPR for Oncology?

Peptide to Antagonize GRPR for Oncology is a peptide commercialized by Novartis, with a leading Phase II program in Metastatic...

Net Present Value Model: Novartis AG's Peptide to Antagonize GRPR for Oncology

Data Insights

Risk adjusted net present value: What is the current valuation of Novartis's Pelacarsen Sodium?

Pelacarsen Sodium is an antisense oligonucleotide commercialized by Novartis, with a leading Phase III program in Cardiovascular Disease. According to...

Net Present Value Model: Novartis AG's Pelacarsen Sodium

Data Insights

Risk adjusted net present value: What is the current valuation of Novartis's Iscalimab?

Iscalimab is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Lupus Nephritis. According to Globaldata,...

Net Present Value Model: Novartis AG's Iscalimab